Sugi Predict

Sugi Predict / Targets / PBRM1

PBRM1

Protein polybromo-1 · Q86U86 · PBRM1 on Sugi Atlas →

40,463 patent compounds predicted against PBRM1, 24,263 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL282066 SCHEMBL282066 0.45 3/20
SCHEMBL143999 SCHEMBL143999 0.78 2/20
SCHEMBL159997 SCHEMBL159997 0.57 2/20
SCHEMBL147041 SCHEMBL147041 0.53 2/20
SCHEMBL212687 SCHEMBL212687 0.50 2/20
SCHEMBL433208 SCHEMBL433208 0.50 2/20
SCHEMBL154430 SCHEMBL154430 0.45 2/20
SCHEMBL115757 SCHEMBL115757 0.44 2/20
SCHEMBL25981 SCHEMBL25981 0.44 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL192933) 0.42 2/20
Biphenyl Biphenyl (SCHEMBL302888) 0.42 2/20
SCHEMBL281203 SCHEMBL281203 0.41 2/20
SCHEMBL409947 SCHEMBL409947 0.35 2/20
SCHEMBL334504 SCHEMBL334504 0.35 2/20
SCHEMBL163526 SCHEMBL163526 0.33 2/20
SCHEMBL28880 SCHEMBL28880 1.00 1/20
SCHEMBL50742 SCHEMBL50742 1.00 1/20
SCHEMBL147608 SCHEMBL147608 1.00 1/20
SCHEMBL203373 SCHEMBL203373 0.88 1/20
SCHEMBL125621 SCHEMBL125621 0.87 1/20

Clinical trials — most relevant to PBRM1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. PHASE2RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) PHASE2COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) PHASE2ACTIVE_NOT_RECRUITING
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
PET Imaging of PARP Activity in Cancer EARLY_PHASE1UNKNOWN
Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma nanCOMPLETED
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors nanCOMPLETED
Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer nanRECRUITING
Pancreatic Cancer Early Detection Consortium nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Characterization of Angelman Syndrome nanCOMPLETED
UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies nanACTIVE_NOT_RECRUITING
Genetic Analysis to Predict the Development of Paget's Disease nanACTIVE_NOT_RECRUITING
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer nanUNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Genetic Study of Families Affected by Paget's Disease of Bone nanCOMPLETED
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms nanRECRUITING
Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Intestinal Carcinoma nanNOT_YET_RECRUITING
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PBRM1 binder may also engage these)

ProteinNameSimilarity
Q90941 — 1.000 Q90941 →
Q8BSQ9 — 1.000 Q8BSQ9 →
Q9Y7N0 — 0.983 Q9Y7N0 →
Q14562 — 0.980 Q14562 →
Q8R5C8 — 0.980 Q8R5C8 →
Q9AR19 — 0.980 Q9AR19 →
Q24564 — 0.980 Q24564 →
Q15326 — 0.980 Q15326 →
Q9Y4G8 — 0.980 Q9Y4G8 →
Q6ZQK5 — 0.979 Q6ZQK5 →
P24583 — 0.979 P24583 →
PTK2B Protein-tyrosine kinase 2-beta 0.979 landscape →
Q7PS12 — 0.979 Q7PS12 →
Q86T65 — 0.979 Q86T65 →
O43295 — 0.979 O43295 →
P70600 — 0.978 P70600 →
F1M386 — 0.978 F1M386 →
F1PBJ0 — 0.978 F1PBJ0 →
P36582 — 0.978 P36582 →
Q9H1H9 — 0.978 Q9H1H9 →
Q9VZI3 — 0.978 Q9VZI3 →
Q9QVP9 — 0.977 Q9QVP9 →
KDM5B Lysine-specific demethylase 5B 0.977 landscape →
Q8CHG7 — 0.977 Q8CHG7 →
Q8BX57 — 0.977 Q8BX57 →
Q18685 — 0.977 Q18685 →
Q5ZK62 — 0.977 Q5ZK62 →
Q5FVC7 — 0.977 Q5FVC7 →
Q86YR7 — 0.977 Q86YR7 →
A2CEA7 — 0.977 A2CEA7 →